Chronic Myeloproliferative Disorders 1st Edition by Tariq Mughal, John M Goldman ISBN 0415415985 9780415415989 by Mughal Tariq, John M. Goldman 0415415985 instant download after payment.

Chronic Myeloproliferative Disorders 1st Edition by Tariq Mughal, John M Goldman - Ebook PDF Instant Download/Delivery: 0415415985, 9780415415989
Full download Chronic Myeloproliferative Disorders 1st Edition after payment

Product details:

ISBN 10: 0415415985 
ISBN 13: 9780415415989
Author: Tariq Mughal, John M Goldman 

With the new classification of chronic myeloproliferative disorders, and the rise of interest in molecularly targeted therapies, this timely text brings together international experts on the topic to discuss the current technologies and their implications for the treatment of patients. This title comprehensively covers chronic myeloid leukemia and Ph-negative chronic myeloproliferative disorders and is an essential resource for all practitioners in Hematologic Oncology.

Chronic Myeloproliferative Disorders 1st Table of contents:

Part I Philadelphia-positive chronic myeloproliferative disorders
1: Chronic myeloid leukemia: a historical perspective
Introduction
The 17th and 18th Centuries
The 19th Century
The 20th Century
The 21st Century
Conclusions and Future Directions
References
2: Cytogenetics and molecular biology of chronic myeloid leukemia
Introduction
Etiology of the BCR-ABL Translocation
The Target Cell of the BCR-ABL Translocation
The BCR-ABL Gene
The BCR and ABL Proteins
Deregulation of BCR-ABL Tyrosine Kinase Activity
BCR-ABL motifs other than SH1 with a critical role for leukemogenesis
The actin-binding domain
Tyrosine 177 of BCR
Chronic Myeloid Leukemia Models
3: Risk stratification models and prognostic variables for chronic myeloid leukemia
Philadelphia-Positive Chronic Myeloid Leukemia
Definition of Accelerated Phase and Blast Crisis
International (Sokal) and European (Hasford) Scores
European Group for Blood and Marrow Transplantation Risk Score
Prognosis of Imatinib Mesylate-Treated Patients
Baseline prognostic factors
Response-Related Prognostic Factors
Acknowledgments
References
4: Clinical aspects of chronic myeloid leukemia
Introduction
Natural History
Clinical Presentation
Clonal Evolution
Risk Stratification
Resistance to Imatinib Mesylate
Conclusions
References
5: Chronic myeloid leukemia: current first-line treatment options
Introduction
Cytotoxic Agents
Interferon Alfa
Imatinib: The Standard of Care in Chronic Myeloid Leukemia
Survival Advantage
Imatinib Dose Schedule
References
6: Chronic myeloid leukemia: new targeted therapies
Introduction
Imatinib Resistance
Incidence
Mechanisms of imatinib resistance
BCR-ABL-dependent mechanisms of resistance
BCR-ABL-independent mechanisms of resistance
Overcoming imatinib resistance
High-dose imatinib
Dasatinib
Phase I study
Phase II studies
Safety data
Optimizing dose and schedule
First-line therapy
Nilotinib
7: Hematopoietic cell transplantation for chronic myeloid leukemia and myelofibrosis
Introduction
Allogeneic Transplant for Chronic Myeloid Leukemia
Source of Stem Cells: Peripheral Blood or Bone Marrow
Conditioning Regimen
Non-Ablative Transplantation
Prognostic Factors
Impact of Pretransplant Imatinib on Outcome
8: Monitoring response to therapy for patients with chronic myeloid leukemia
History of Monitoring Minimal Residual Disease
Current Monitoring Strategies for Chronic Myeloid Leukemia-Chronic Phase Patients on Tyrosine Kinase Inhibitors
Baseline investigation
Hematological response
Cytogenetic response
Real-time quantitative polymerase chain reaction
9: Immunotherapy in chronic myeloid leukemia
Molecular Features
BCR-ABL Fusion Peptides
Immunogenicity of BCR-ABL Junctional Peptides
Other Leukemia-Associated Antigens
Dendritic Cells in Chronic Myeloid Leukemia
Effects of Tyrosine Kinase Inhibitors on the Immune System
Clinical Strategies
Conclusions
References
10: Potential treatment algorithms and future directions for patients with chronic myeloid leukemia
Introduction
A Potential Treatment Algorithm for a Newly Diagnosed Patient with Chronic Myeloid Leukemia in Chronic Phase
A Potential Treatment Algorithm for a Patient with Chronic Myeloid Leukemia in Chronic Phase who is Resistant or Intolerant to Imatinib
A Potential Treatment Algorithm for a Patient with Chronic Myeloid Leukemia in Chronic Phase who is Resistant to all Currently available Tyrosine Kinase Inhibitors
Future Approaches
Conclusions
References
Part II Philadelphia-negative chronic myeloproliferative disorders
11: History of BCR-ABL-negative chronic myeloproliferative disorders
References
12: BCR-ABL-negative atypical chronic myeloproliferative disorders
Introduction
BCR-ABL-Negative Chronic Myeloid Leukemia and Related Atypical Disorders
Challenges at the Beginning of the Current Century
The Molecular Pathogenesis of BCR-ABL-Negative Myeloproliferative Disorders
Overview
PDGFRA fusion genes
13: Systemic mastocytosis
Introduction
Mastocytosis
14: Polycythemia vera
Seminal Studies up to the Year 2000
Pathogenesis
Diagnosis
Therapy
Challenges at the Beginning of this Century
Important Developments Since the Year 2000
Pathogenesis
Diagnosis
Therapy
15: Chronic idiopathic myelofibrosis
Introduction
Clinical Features
Pathogenetic Insights and Novel Diagnostic Criteria for Chronic Idiopathic Myelofibrosis
Management of Patients with Myelofibrosis
Cytotoxic therapy
Erythropoietin
Interferon alfa
Stem cell transplantation
16: Essential thrombocythemia
Introduction
Epidemiology
Molecular Pathogenesis
The JAK2 V617F and MPL W515 mutations
Pathophysiology
Mouse models
Co-operating mutations
V617F homozygosity
Signaling
Clinical Features and Natural History of Essential Thrombocythemia
Overall survival
Thrombosis and microvascular ischemia
Hemorrhage
17: Transplant options for patients with BCR-ABL-negative chronic myeloproliferative disorders
Introduction
Autologous Stem Cell Transplantation
Allogeneic Stem Cell Transplantation after Standard Myeloablative Conditioning
Allogeneic Stem Cell Transplantation after Dose-Reduced Conditioning
Role of Splenectomy Prior to Transplantation
The Role of JAK2 Mutation in the Transplant Setting
Bone Marrow Fibrosis Regression
Risk Assessment and Allogeneic Stem Cell Transplantation
References
18: Non-transplant therapeutic strategies for patients with BCR-ABL-negative chronic myeloproliferative disorders
Introduction
Imatinib in BCR-ABL-Negative Myeloproliferative Disorders
Targeting Activated JAK2 Proteins
Targeting Components Downstream of JAK2
Outlook

People also search for Chronic Myeloproliferative Disorders 1st:

chronic myeloproliferative disorders
    
what do all chronic myeloproliferative disorders share
    
chronic myeloproliferative disorder meaning
    
chronic myeloproliferative disease pathology outlines
    
myeloproliferative disorder chronic
    
chronic myeloproliferative disease vs myelofibrosis
    
chronic myeloproliferative disease meaning

Tags: Tariq Mughal, John M Goldman, Chronic, Myeloproliferative